• Explore /
  • Poster
  • / Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study.

Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study.

Abstract Poster

Authors

null

Howard I. Scher

Memorial Sloan-Kettering Cancer Center, New York, NY

Howard I. Scher , Karim Fizazi , Fred Saad , Mary-Ellen Taplin , Cora N. Sternberg , Kurt Miller , Ronald De Wit , Peter Mulders , Mohammad Hirmand , Bryan Selby , Johann Sebastian De Bono

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session A: Prostate Cancer

Track

Prostate Cancer

Sub Track

Prostate Cancer

Clinical Trial Registration Number

NCT00974311

Citation

J Clin Oncol 30, 2012 (suppl 5; abstr LBA1)

DOI

10.1200/jco.2012.30.5_suppl.lba1

Abstract #

LBA1

Poster Bd #

A2

Abstract Disclosures

Similar Posters

First Author: Edwina S. Baskin-Bey

First Author: Earle F Burgess

Poster

2023 ASCO Genitourinary Cancers Symposium

Androgen receptor (AR) mutations in men with metastatic castration-resistant prostate cancer (mCRPC): Incidence and natural history.

Androgen receptor (AR) mutations in men with metastatic castration-resistant prostate cancer (mCRPC): Incidence and natural history.

First Author: Alice Bernard-Tessier

First Author: Andrew J. Armstrong